Jennifer Bath, Ph.D.
CEO and President, MindWalk Holdings Corp.
- Role
- CEO and President, MindWalk Holdings Corp. at MindWalk Corp. (formerly IPA ImmunoPrecise Antibodies)
About Jennifer Bath, Ph.D.
Dr. Jennifer Bath, PhD, is the CEO and President of MindWalk Holdings Corp. (NASDAQ: HYFT), a Bio-Native AI company transforming biologics discovery and drug development. With a PhD in Cellular and Molecular Biology specializing in immunology and biochemistry, Jennifer has built a career at the rare intersection of deep biological science, bioinformatics, and artificial intelligence.Before leading MindWalk, Jennifer held a tenured Associate Professorship in Cellular and Molecular Biology and founded the Concordia Global Vaccine Institute, directing programs to discover and validate biologics for neglected tropical diseases. She subsequently held executive roles across biotechnology and contract research organizations, including a senior post at Aldevron, where she led global client relations and high-value target teams—translating complex scientific and market challenges into operational strategy for pharmaceutical and biotech clients globally.At MindWalk, Jennifer leads a team of scientists and technologists building the BioIntelligence Ecosystem — integrating LensAI™, powered by HYFT® technology, with over 25 billion biological relationships and advanced wet lab capabilities. Under her leadership, MindWalk has advanced dozens of client molecules to the clinic and launched ReefIQ™, a biological context layer purpose-built for AI drug discovery. Jennifer is a strategic leader who believes the future of drug development depends not on more AI, but on AI that understands biology - with context, traceability, and explainability at its core.
Experience
CEO and President, MindWalk Holdings Corp.
MindWalk Corp. (formerly IPA ImmunoPrecise Antibodies)
Nov 2025 — Present
Chairman of the Board
BioStrand (a subsidiary of IPA Therapeutics)
Apr 2022 — Present · Limburg, Belgium
BioStrand offers an AI-powered revolutionary methodology for rapidly analyzing and mining a broad range of biological data to identify patterns and variations in multi-omics data and detect structural anchor points to drive innovation in numerous fields including precision medicine, drug and vaccine development, and target discovery.
Executive Director
ImmunoPrecise Antibodies Ltd
May 2018 — Present · Victoria, British Columbia
Managing Director
U-Protein Express BV
Apr 2018 — Present · Utrecht Area, Netherlands
Managing Director
ModiQuest Research B.V.
Apr 2018 — Present · Oss, Netherlands
President and CEO
ImmunoPrecise Antibodies Ltd.
Feb 2018 — Nov 2025 · Victoria, British Columbia, Canada
ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company’s experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise’s full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. Our services include, but are not limited to, proprietary B cell sorting, screening and sequencing; custom, immune and naïve phage display production and screening; expertise with transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening and clone-picking; cryopreservation; and custom antigen modeling, design and manufacturing.
Global Director
Aldevron
Apr 2016 — Feb 2018 · Freiburg, Baden-Württemberg, Germany
As Aldevron's Global Director of Client Relations, Jennifer heads up Aldevron's global client relations and RG project management, while serving as a key outward facing member of the executive team to pharmaceutical companies and biotech alike. She defines business strategies by applying knowledge based on the science, technology and the competitive landscape. Serving as a key technical specialist, she is responsible for retention and growth of the existing client base through individual efforts and efforts of the management team to deliver profitable, quality services. Jennifer manages client assignments, builds strong public relationships. As an additional external functional, Jennifer serves as the technical lead for Aldevron's Freiburg team in antibody therapeutics, operates globally and reports to Aldevron's founder and CEO.
Director of Client Relations
Aldevron
Jul 2015 — Apr 2016 · Freiburg, Baden-Württemberg, Germany
Jennifer applies personal and business skills to build key relationships with pharmaceutical companies while working to unify and motivate cross-functional teams toward strategic thinking and marketing solutions to achieve our corporate business goals.
Associate Professor of Cellular and Molecular Biology
Concordia College
May 2013 — Jul 2015 · Moorhead, MN
Received Tenure: May 2013 Principal Investigator: Vaccine and Therapeutic Design, Development, Formulation and Testing Program Director for Vaccinology Minor, Concordia College. Professor of Cellular and Molecular Biology. Main courses: Advanced Cellular Biology, Genetics and Molecular Biology, Introduction to Cellular Biology, and Vaccine Immunology. Principle investigator of research team focusing on mechanisms of immunomodulation of host cell responses during helminth chronic infections. Investigation of mechanisms involved in cellular differentiation of Th0 cells to Th1 and Th2 cells, and the use of exogenous antigens to alter differentiation within occupied host tissues. We focus research efforts on antihelminthic treatments, including the identification and analysis of targets for biologic therapeutics and small molecule drug design, as well as the development of cell-mediated and humoral-based vaccine candidates.
Founder and Executive Director
CC Global Vaccine Institute
Sep 2009 — Aug 2015 · Moorhead, MN
As founder of the CCGVI, Dr. Bath established the business model, mission, and scope of the institute's activities. Her work focused on the financial aspects of federal, state, and private funding, while hiring and overseeing employees from a financial, corporate, and scientific perspective. The mission of the institute is primarily focused on the fight against 'diseases of poverty', or neglected tropical diseases that afflict impoverished individuals living mainly in tropical climates. The CCGVI focuses on discovering, developing and testing therapeutic and prophylactic treatments against targets specific to soil-transmitted helminths. Our goal is to educate individuals and groups about the multi-factorial barriers (educational, political, etc.) that exist to sustain these diseases and, through our R&D programs, have a global impact in helping to reduce the suffering caused by these preventable and devastating diseases. ***As of July 2015, all active CCGVI R&D programs have been moved to USD under the co-direction of Dr. Joseph Provost.
Consultant, Strategic and Operational Business Practices
Talem Biologics Consulting Group
2009 — Aug 2015 · Minneapolis, MN
Talem Biologics is a professional life sciences consulting agency dedicated to advancing the fields of vaccine and therapeutic antibody discovery, contract research, cell and gene therapy, strategy and business operations, and regulatory communications through dependable advising, collaboration, training and education, outcome-based research, support of ethical standards, and an ongoing review of best practices.
Assistant Professor
Concordia College
May 2005 — Jun 2013 · Moorhead, MN
Education
North Dakota State University
Doctor of Philosophy (Ph.D.) · Cellular and Molecular Biology
1996 — 2000
Harvard Business School
Certificate · Corporate Board Effectivenesss
2020 — 2020
Aix-Marseille University
Certificat · French Language and Culture
1993 — 1994
University of Kansas
B.A. · Biology, Human Genetics
1990 — 1995
Skills
- NASDAQ
- Fundraising
- Communication
- Campaigns
- Public Speaking
- Strategy Consulting
- Business Development
- Metabolomics
- Long-term Vision
- Social Policy
- Negotiation
- Marketing
- Regulatory Affairs
- Problem Solving
- Contract Research and Development
- Economic Development
- Protein Purification
- Team Leadership
- Biotechnology
- Professional Skills
- Business Planning
- Genomics
- Executive Management
- Strategy
- Strategic Thinking
- Equity Capital Markets
- Interpersonal Skills
- Therapeutics
- Finance
- Congressional Lobbying
- Antibody Development
- Gene Therapy
- Contract Research Organization (CRO)
- Pre-clinical Studies
- Mergers & Acquisitions (M&A)
- Biotechnology Industry
- Health Policy
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.